Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MEDI7247 · 2 trials · 9 indications
To assess the occurrence of adverse events
To assess the occurrence of serious adverse events
To assess the occurrence of toxicities and abnormal laboratory results that may limit further dose administration
To assess serum chemistry, hematology, urinalysis and coagulation parameters
to assess changes in vital signs
to assess changes in ECG
to assess changes in serum chemistry, hematology, urinalysis, and coagulation parameters
To assess by the occurrence of adverse events (AEs)
To assess by the occurrence of serious adverse events (SAEs)
To assess by the occurrence of non-Hematologic and hematologic toxicities, AEs, and abnormal laboratory results.
To assess body temperature, blood pressure, and heart rate
To assess using twelve-lead ECG recordings
| Arm | Type | Description |
|---|---|---|
| NSCLC-Sq/HNSCC | EXPERIMENTAL | Patients with advanced or metastatic NSCLC-Sq or HNSCC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior standard of care regimen (platinum-based for HNSCC). PDL-1 positive patients should have received previous PD-1 or PD-L1 inhibitor where available. |
| Small Cell Lung Cancer | EXPERIMENTAL | Patients with advanced SCLC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior standard of care regimen. |
| Colorectal Cancer | EXPERIMENTAL | Patients with metastatic adenocarcinoma of the colon or rectum who have received and have progressed, or have documented intolerance, on prior thymidylate synthase inhibitor (eg, 5-fluorouracil (5-FU), capecitabine, raltitrexed, tegafur-uracil (UFT), irinotecan, and oxaliplatin for metastatic disease. If patients progress within 6 months of their last dose of adjuvant therapy this should be considered as a line of therapy in the metastatic setting. Patients with known RAS wildtype tumors must have received and progressed, or have documented intolerance, on anti-EGFR antibody. Patients with microsatellite instability-high or deficient mismatch repair tumors, must have received and progressed, or have documented intolerance on a PD-1 inhibitor, or PD-1 inhibitor plus cytotoxic T-lymphocyte antigen-4 inhibitor treatment where available. |
| Pancreatic Ductal Adenocarcinoma | EXPERIMENTAL | Patients with unresectable, locally advanced or metastatic PDAC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior line of treatment. |
| Metastatic Castration-Resistant Prostate Cancer | EXPERIMENTAL | Patients with mCRPC who have received prior treatment with abiraterone or enzalutamide, with or without a prior taxane-based chemotherapy in the mCRPC setting. |
| Other advanced/metastatic target expressing solid tumors | EXPERIMENTAL | Patients with advanced or metastatic solid tumors not defined by other treatment arms who have positive expression of the protein target and have exhausted all approved therapies |
| acute myeloid leukemia | EXPERIMENTAL | Patients with R/R AML by World Health Organization (WHO) classification (Arber et al, 2016) who have failed prior standard therapy and for whom no standard therapies are available |
| Multiple Myeloma | EXPERIMENTAL | Patients with R/R MM who have failed prior standard therapy(ies) which should include immunomodulatory agents and proteasome inhibitors and for whom there is no standard salvage regimen. |
| Diffuse Large B-cell Lymphoma | EXPERIMENTAL | Patients with R/R DLBCL who have failed prior standard therapy(ies) and for whom there is no standard salvage regimen. |
| Name | Type | Description |
|---|---|---|
| MEDI7247 | DRUG | Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule |
Inclusion Criteria: 1. Confirmed diagnosis of advanced or metastatic select solid tumors and either progression on or documented intolerance to standard therapies 2. Age ≥ 18 years at the time of screening. 3. Written informed consent and any locally required authorization 4. Eastern Cooperative On...
MEDI7247 is an investigational small molecule being studied for the treatment of Acute Myeloid Leukemia and Non Small Cell Lung Cancer Squamous (NSCLC-Sq). It has also been evaluated in other hematological malignancies and advanced solid tumors, including Multiple Myeloma, Diffuse Large B-cell Lymphoma, Head and Neck Squamous Cell Carcinoma, and Small Cell Lung Cancer.
MEDI7247 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker symbol AZN. The drug is currently in Phase 1 clinical development for oncology indications.
MEDI7247 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to evaluate its safety and efficacy in patients.
MEDI7247 has been studied in two completed Phase 1 clinical trials. Trial NCT03106428 evaluated the drug in patients with relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia. Trial NCT03811652 evaluated MEDI7247 in advanced or metastatic solid tumors, including Non Small Cell Lung Cancer Squamous.
MEDI7247 is the primary name for this investigational drug. No alternative names have been reported for MEDI7247 in the available clinical trial information. It is identified by its compound name in the studies registered under the National Clinical Trial numbers NCT03106428 and NCT03811652.
MEDI7247 is a small molecule therapeutic being developed for oncology indications. The specific molecular target or mechanism of action for MEDI7247 has not been disclosed in the available clinical trial information, so its precise biological function remains under investigation.